0000000000001346

AUTHOR

Irene Pillitteri

showing 6 related works from this author

CHK1 inhibitor sensitizes resistant colorectal cancer stem cells to nortopsentin

2021

Summary Limited therapeutic options are available for advanced colorectal cancer (CRC). Herein, we report that exposure to a neo-synthetic bis(indolyl)thiazole alkaloid analog, nortopsentin 234 (NORA234), leads to an initial reduction of proliferative and clonogenic potential of CRC sphere cells (CR-CSphCs), followed by an adaptive response selecting the CR-CSphC-resistant compartment. Cells spared by the treatment with NORA234 express high levels of CD44v6, associated with a constitutive activation of Wnt pathway. In CR-CSphC-based organoids, NORA234 causes a genotoxic stress paralleled by G2-M cell cycle arrest and activation of CHK1, driving the DNA damage repair of CR-CSphCs, regardless…

0301 basic medicineCell cycle checkpointColorectal cancerScienceSettore MED/50 - Scienze Tecniche Mediche Applicate02 engineering and technologyGenotoxic StressArticleMolecular Physiology03 medical and health sciencesSettore MED/04 - PATOLOGIA GENERALERabusertibmedicineClonogenic assayCancerMultidisciplinarybusiness.industryQWnt signaling pathwayDrugsCancerCell Biology021001 nanoscience & nanotechnologymedicine.disease030104 developmental biologyCancer researchSettore MED/46 - Scienze Tecniche Di Medicina Di LaboratorioStem cell0210 nano-technologybusinesscolorectal cancer cancer stem cells alkaloids DNA damage repair CHK1.iScience
researchProduct

Dual Inhibition of Myc Transcription and PI3K Activity Effectively Targets Colorectal Cancer Stem Cells

2022

Despite advances in the curative approach, the survival rate of advanced colorectal cancer (CRC) patients is still poor, which is likely due to the emergence of cancer cell clones resistant to the available therapeutic options. We have already shown that CD44v6-positive CRC stem cells (CR-CSCs) are refractory toward standard anti-tumor therapeutic agents due to the activation of the PI3K pathway together with high HER2 expression levels. Tumor microenvironmental cytokines confer resistance to CR-CSCs against HER2/PI3K targeting by enhancing activation of the MAPK pathway. Here, we show that the CSC compartment, spared by BRAF inhibitor-based targeted therapy, is associated with increased ex…

cancer stem cellsCancer ResearchOncologySettore MED/04 - PATOLOGIA GENERALECancer stem cellCombination therapies.anti-tumor drug resistanceanti-tumor drug resistance; colorectal cancer; combination therapies; cancer stem cellsNeoplasms. Tumors. Oncology. Including cancer and carcinogenscolorectal cancerSettore MED/46 - Scienze Tecniche Di Medicina Di Laboratoriocombination therapiesRC254-282Cancers
researchProduct

Recapitulating thyroid cancer histotypes through engineering embryonic stem cells

2023

AbstractThyroid carcinoma (TC) is the most common malignancy of endocrine organs. The cell subpopulation in the lineage hierarchy that serves as cell of origin for the different TC histotypes is unknown. Human embryonic stem cells (hESCs) with appropriate in vitro stimulation undergo sequential differentiation into thyroid progenitor cells (TPCs-day 22), which maturate into thyrocytes (day 30). Here, we create follicular cell-derived TCs of all the different histotypes based on specific genomic alterations delivered by CRISPR-Cas9 in hESC-derived TPCs. Specifically, TPCs harboring BRAFV600E or NRASQ61R mutations generate papillary or follicular TC, respectively, whereas addition of TP53R248…

MultidisciplinaryGeneral Physics and AstronomyGeneral ChemistryGeneral Biochemistry Genetics and Molecular BiologyThyroid cancer thyroid progenitor cells genetic mutation model CD44 TIMP1 KISS1 KISS1R.
researchProduct

Effective targeting of breast cancer stem cells by combined inhibition of Sam68 and Rad51

2022

AbstractBreast cancer (BC) is the second cause of cancer-related deceases in the worldwide female population. Despite the successful treatment advances, 25% of BC develops resistance to current therapeutic regimens, thereby remaining a major hurdle for patient management. Current therapies, targeting the molecular events underpinning the adaptive resistance, still require effort to improve BC treatment. Using BC sphere cells (BCSphCs) as a model, here we showed that BC stem-like cells express high levels of Myc, which requires the presence of the multifunctional DNA/RNA binding protein Sam68 for the DNA-damage repair. Analysis of a cohort of BC patients displayed that Sam68 is an independen…

cancer stem cellCancer Researchtherapy resistanceDNA RepairSettore MED/50 - Scienze Tecniche Mediche ApplicateCell Cycle ProteinsBreast NeoplasmsTriple Negative Breast NeoplasmsMycCell LineBreast cancerSettore MED/04 - PATOLOGIA GENERALECell Line TumorGeneticsHumansMolecular BiologyAdaptor Proteins Signal TransducingTumorSignal TransducingRNA-Binding ProteinsAdaptor ProteinsDNA-Binding ProteinsSam68Neoplastic Stem CellsFemaleRad51 RecombinaseSettore MED/46 - Scienze Tecniche Di Medicina Di Laboratorio
researchProduct

PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells

2020

ObjectiveCancer stem cells are responsible for tumour spreading and relapse. Human epidermal growth factor receptor 2 (HER2) expression is a negative prognostic factor in colorectal cancer (CRC) and a potential target in tumours carrying the gene amplification. Our aim was to define the expression of HER2 in colorectal cancer stem cells (CR-CSCs) and its possible role as therapeutic target in CRC resistant to anti- epidermal growth factor receptor (EGFR) therapy.DesignA collection of primary sphere cell cultures obtained from 60 CRC specimens was used to generate CR-CSC mouse avatars to preclinically validate therapeutic options. We also made use of the ChIP-seq analysis for transcriptional…

0301 basic medicineReceptor ErbB-2Colorectal cancerCetuximabcolorectal cancermedicine.disease_cause03 medical and health sciencesAntineoplastic Agents Immunological0302 clinical medicineSettore MED/04 - PATOLOGIA GENERALECancer stem cellstem cellsTumor Cells CulturedmedicineAdjuvant therapyAnimalsHumansEpidermal growth factor receptorProtein kinase BPI3K/AKT/mTOR pathwayPhosphoinositide-3 Kinase InhibitorsMitogen-Activated Protein Kinase Kinasesdrug resistancebiologybusiness.industryGastroenterologyTrastuzumabmedicine.diseaseantibody targeted therapy030104 developmental biologyDrug Resistance Neoplasm030220 oncology & carcinogenesisNeoplastic Stem CellsCancer researchbiology.proteinKRASPhosphatidylinositol 3-KinaseStem cellColorectal Neoplasmsbusiness
researchProduct

Adipose stem cell niche reprograms the colorectal cancer stem cell metastatic machinery.

2021

Obesity is a strong risk factor for cancer progression, posing obesity-related cancer as one of the leading causes of death. Nevertheless, the molecular mechanisms that endow cancer cells with metastatic properties in patients affected by obesity remain unexplored. Here, we show that IL-6 and HGF, secreted by tumor neighboring visceral adipose stromal cells (V-ASCs), expand the metastatic colorectal (CR) cancer cell compartment (CD44v6 + ), which in turn secretes neurotrophins such as NGF and NT-3, and recruits adipose stem cells within tumor mass. Visceral adipose-derived factors promote vasculogenesis and the onset of metastatic dissemination by activation of STAT3, which inhibits miR-200…

MaleCancer microenvironmentobesityStromal cellColorectal cancerScienceSettore MED/50 - Scienze Tecniche Mediche ApplicateGeneral Physics and AstronomyAdipose tissueMice SCIDSCIDmetastasis.General Biochemistry Genetics and Molecular BiologyArticleMiceVasculogenesisSettore MED/04 - PATOLOGIA GENERALEmedicineAnimalsHumansNeoplasm MetastasisStem Cell NicheZinc Finger E-box Binding Homeobox 2Tumor microenvironmentMultidisciplinarybusiness.industryHepatocyte Growth FactorInterleukin-6Stem CellsQadipose stromal cellCancerCD44v6General Chemistrymedicine.diseaseCellular ReprogrammingColorectal cancerMicroRNAsAdipose TissueCancer cellColonic NeoplasmsCancer researchNeoplastic Stem Cellsconsensus molecular subtypeStem cellSettore MED/46 - Scienze Tecniche Di Medicina Di LaboratoriobusinessNature communications
researchProduct